Badanie nad RO7204239 u pacjentów z dystrofią mięśniową twarzowo-łopatkowo-ramieniową

Facioscapulohumeral muscular dystrophy (FSHD) is a genetic disorder that causes muscle weakness, primarily affecting the face, shoulders, and upper arms. This study is focused on evaluating a new treatment called RO7204239, which is a type of protein known as a humanised IgG1 monoclonal antibody. This protein is designed to target and interact with a specific substance in the body called latent myostatin, which is involved in muscle growth and development. The study aims to understand how this treatment affects the body, its safety, and how well it is tolerated by participants with FSHD.

The study involves participants receiving either the RO7204239 treatment or a placebo, which is a substance with no active medication. The treatment is given as a solution for injection under the skin. Throughout the study, participants will undergo various assessments, including magnetic resonance imaging (MRI), to monitor changes in muscle volume and other health indicators. The study will also track any side effects or reactions to the treatment. The goal is to gather information on the effectiveness and safety of RO7204239 in managing symptoms of FSHD.

This research is conducted in a controlled and randomized manner, meaning participants are randomly assigned to receive either the treatment or placebo without knowing which one they are receiving. This approach helps ensure the results are unbiased and reliable. The study will continue for a set period, during which participants will be closely monitored by healthcare professionals to ensure their safety and well-being.